 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||||||| Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India
Trial completion: Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines (clinicaltrials.gov) - Apr 23, 2024
P3, N=1340, Completed, Sponsor: Novavax
Active, not recruiting --> Completed
- ||| Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India, NVX-CoV2515 / Novavax
P3 data, Journal: Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial. (Pubmed Central) - Nov 16, 2023
NVX-CoV2515 elicited a superior neutralizing antibody response against the Omicron BA.1 subvariant compared with NVX-CoV2373 when administered as a fourth dose. Safety data were consistent with the established safety profile of NVX-CoV2373.
- Immunogenicity and Safety of a Heterologous Booster Dose of Omicron Subvariant (BA.1 and BA.5) and Bivalent SARS-CoV-2 Recombinant Spike Protein Vaccines: A Phase 3, Randomized, Clinical Trial (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_1162;
- ||| Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India
Trial completion date: Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines (clinicaltrials.gov) - Aug 29, 2023
P3, N=1340, Active, not recruiting, Sponsor: Novavax
Safety data were consistent with the established safety profile of NVX-CoV2373. Trial completion date: Jul 2023 --> Feb 2024
- | Spikevax (elasomeran) / Moderna
Journal: Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates. (Pubmed Central) - May 16, 2023
The protection against SARS-CoV-2 BA.5 infection in the upper respiratory airways correlated with binding, neutralizing, and ADNP activities of the serum antibody. These data have important implications for COVID-19 vaccine development, as vaccines that lower nasopharyngeal virus may help to reduce transmission.
- ||||| Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India
Enrollment change: Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines (clinicaltrials.gov) - Nov 25, 2022
P3, N=1340, Active, not recruiting, Sponsor: Novavax
These data have important implications for COVID-19 vaccine development, as vaccines that lower nasopharyngeal virus may help to reduce transmission. N=2090 --> 1340
- || Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India, NVX-CoV2515 / Novavax
We in no way have all the data. NVX-CoV2373 v mRNA BA.5 for BA.2.75? NVX-CoV2515 v mRNA BA.5 for BA.2.75? NVX-CoV2540 v mRNA BA.5 vs BA.2.75? NVX-CoV2540 v mRNA BA.5 for BA.5? And so on... (Twitter) - Aug 30, 2022
- ||||| Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India
Enrollment change: Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines (clinicaltrials.gov) - Aug 11, 2022
P3, N=2090, Active, not recruiting, Sponsor: Novavax
N=2090 --> 1340 N=1340 --> 2090
- ||| NVX-CoV2515 / Novavax
Novavax just finished their version, NVX-CoV2515, to the Omicron variant on July 17, 2022. But it says the study completion date is next July, 2023? https://t.co/tXjoo1ZUpT https://t.co/E4gEtgY1O7 (Twitter) - Aug 8, 2022
- ||||| Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India
Enrollment closed: Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines (clinicaltrials.gov) - Jul 23, 2022
P3, N=1340, Active, not recruiting, Sponsor: Novavax
N=1340 --> 2090 Not yet recruiting --> Active, not recruiting
- ||||| Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India
Enrollment change: Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines (clinicaltrials.gov) - Jun 8, 2022
P3, N=1340, Not yet recruiting, Sponsor: Novavax
Not yet recruiting --> Active, not recruiting N=980 --> 1340
- |||||||||| Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India
New P3 trial: Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines (clinicaltrials.gov) - May 11, 2022
P3, N=980, Not yet recruiting, Sponsor: Novavax